2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow CGC 11047: new trials by email Literature Review of CGC 11047 trials Research Report on CGC 11047
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD CGC-11047 - Age Related Macular Degeneration | Phase 1 | Completed | Progen Pharmaceuticals | 43 | 2007-04-01 | 2012-08-06 |
| Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer CGC-11047 - Prostate Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 23 | 2006-06-01 | 2015-10-02 |
| Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab - Cancer | Phase 1 | Completed | Progen Pharmaceuticals | 172 | 2006-05-01 | 2016-07-21 |
Lymphoma (1) · Macular Degeneration (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Progen Pharmaceuticals (2) · University of Wisconsin, Madison (1)
United States (3) · Mexico (1) · Russia (1)
Joe Stephenson, MD (1) · Peter Campochiaro, MD (1)